Oppenheimer set a $28.00 price objective on Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Wednesday. The firm currently has a buy rating on the stock.

Several other equities analysts have also issued reports on the company. Cowen restated a buy rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Piper Jaffray Companies restated an overweight rating and set a $30.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st. Roth Capital assumed coverage on Syros Pharmaceuticals in a research report on Monday, October 23rd. They set a neutral rating and a $15.00 price target on the stock. Zacks Investment Research upgraded Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 17th. Finally, JMP Securities upgraded Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 price target on the stock in a research report on Thursday, September 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. Syros Pharmaceuticals has an average rating of Buy and an average target price of $26.14.

Syros Pharmaceuticals (NASDAQ SYRS) traded up $0.01 on Wednesday, reaching $8.99. The company had a trading volume of 329,187 shares, compared to its average volume of 596,297. Syros Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.53). analysts predict that Syros Pharmaceuticals will post -2.12 earnings per share for the current year.

In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn acquired 15,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $9.08 per share, for a total transaction of $136,200.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju acquired 109,774 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was acquired at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock worth $63,185,000 after buying an additional 418,061 shares during the period. Redmile Group LLC lifted its stake in shares of Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after purchasing an additional 20,520 shares during the period. Vanguard Group Inc. lifted its stake in shares of Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after purchasing an additional 250,507 shares during the period. State Street Corp lifted its stake in shares of Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of Syros Pharmaceuticals by 15.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after purchasing an additional 17,330 shares during the period. Institutional investors and hedge funds own 58.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/16/oppenheimer-reiterates-28-00-price-target-for-syros-pharmaceuticals-syrs.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Stock Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related stocks with our FREE daily email newsletter.